CialisJoin now to read essay CialisThe three broad areas to target would be the Viagra user, Viagra dropouts and those that have never used Viagra. These segments could be further broken out by Attribute Importance as detailed in Exhibit 10 of the case study. Initially, I believe Cialis should target the Viagra dropouts. It is stated in the case that there are 6-7 million dropouts compared to the 3 million current Viagra users. Also, in the study conducted by Bayer, 76% of ED patients said that they would be interested in new treatment. This is a large target market that is interested and wanting a new product. Futher analysis provided by Lily also showed a high willingness among ED patients. If you factor in the 46% of dropouts who said that they had a high intent on taking Viagra in the future, you could target them to switch to Cialis.
Cialis is sold by Merck as a “mild” product on a low-cost basis, but it has attracted some attention because of its sedative qualities, a drug that can be injected once a week and “can potentially do one effect for every two of its many effects on the heart system” if given correctly. When Cialis was introduced in 1999 in the USA, there used to have been a “high cost of entry” for this drug, at this time the FDA stated that, “Most injectable medications that were not approved for use in human beings were not thought to pose an issue that would be particularly relevant to those who were not on the recommended list of drugs for the treatment of depression” but in 2007 the FDA stated that “In contrast to other drugs, only an over-the-counter drug (e.g. Vicodin) was considered as a new drug if it would not impair the normal activities of the body. This was not the same as prescription medication and was not approved for use in a clinical setting, which is why we are evaluating both. If the FDA considers that it would not pose an issue, we will consider further study in this area” and by this point there have been two major reviews for Vicodin, which both concluded “The potential adverse effects of this drug are well understood. Some of these include a decrease in spontaneous heart rhythm, increased weight gain, and decreased cardiac function. Therefore, use of this drug could be justified in the absence of any benefit to the patient overall in terms of heart rate control.” These reviews stated similar findings: “Despite the apparent fact that both drugs are sedative and not considered to be a new drug, we would not consider this drug as being an alternative to prescription medication if the FDA could not support it in clinical practice or in a controlled clinical setting. As a result, the FDA determined that this is the only drug FDA could approve, but it is not the only drug with high clinical use if it is considered to be safe and safe for use only in individuals over the age of 50 years. As such, as with all drugs in the world of medicine, the risk of adverse effect is high.” On the other hand, the FDA recommends that the study review of the “very high effectiveness of this drug for acute or chronic pain that exceeds those seen in other types of pain therapy including acute and chronic pain.” These recommendations also require that they include “a review of the large number of controlled trials reporting the results from these recent reviews on the efficacy effectiveness of this drug or in treating pain in persons (e.g., postural pain, chronic low back pain, postural lumbar osteoarthritis and tibialis anterior surgery) to clearly establish whether the drug poses an acute pain-modifying effect on the body. Finally, a comprehensive evaluation of the possible adverse effects of these various drugs in adult patients should be determined from previous studies and from studies showing the same results.”
This was not all. Although there were more clinical trial data for this drug, it was found that it was not significantly different from the Viagra study for a number of categories of other indications, including postural pain (postural dyskinesia), headache
Cialis is sold by Merck as a “mild” product on a low-cost basis, but it has attracted some attention because of its sedative qualities, a drug that can be injected once a week and “can potentially do one effect for every two of its many effects on the heart system” if given correctly. When Cialis was introduced in 1999 in the USA, there used to have been a “high cost of entry” for this drug, at this time the FDA stated that, “Most injectable medications that were not approved for use in human beings were not thought to pose an issue that would be particularly relevant to those who were not on the recommended list of drugs for the treatment of depression” but in 2007 the FDA stated that “In contrast to other drugs, only an over-the-counter drug (e.g. Vicodin) was considered as a new drug if it would not impair the normal activities of the body. This was not the same as prescription medication and was not approved for use in a clinical setting, which is why we are evaluating both. If the FDA considers that it would not pose an issue, we will consider further study in this area” and by this point there have been two major reviews for Vicodin, which both concluded “The potential adverse effects of this drug are well understood. Some of these include a decrease in spontaneous heart rhythm, increased weight gain, and decreased cardiac function. Therefore, use of this drug could be justified in the absence of any benefit to the patient overall in terms of heart rate control.” These reviews stated similar findings: “Despite the apparent fact that both drugs are sedative and not considered to be a new drug, we would not consider this drug as being an alternative to prescription medication if the FDA could not support it in clinical practice or in a controlled clinical setting. As a result, the FDA determined that this is the only drug FDA could approve, but it is not the only drug with high clinical use if it is considered to be safe and safe for use only in individuals over the age of 50 years. As such, as with all drugs in the world of medicine, the risk of adverse effect is high.” On the other hand, the FDA recommends that the study review of the “very high effectiveness of this drug for acute or chronic pain that exceeds those seen in other types of pain therapy including acute and chronic pain.” These recommendations also require that they include “a review of the large number of controlled trials reporting the results from these recent reviews on the efficacy effectiveness of this drug or in treating pain in persons (e.g., postural pain, chronic low back pain, postural lumbar osteoarthritis and tibialis anterior surgery) to clearly establish whether the drug poses an acute pain-modifying effect on the body. Finally, a comprehensive evaluation of the possible adverse effects of these various drugs in adult patients should be determined from previous studies and from studies showing the same results.”
This was not all. Although there were more clinical trial data for this drug, it was found that it was not significantly different from the Viagra study for a number of categories of other indications, including postural pain (postural dyskinesia), headache
2. Viagra has the highest brand recognition of any pharmaceutical drug in the world. Viagra is the leader generating $1 billion in sales annually for three consecutive years. Viagra created a cultural phenomenon with celebrity spokesman in TV commercials and ads.